G W Amsden1, G Foulds, K Thakker. 1. The Clinical Pharmacology Research Center, Research Institute and Departments of Pharmacy and Medicine, Bassett Healthcare, Cooperstown, New York, USA, guy.amsden@bassett.org.
Abstract
BACKGROUND: Azithromycin, fluconazole and cotrimoxazole (trimethoprim-sulfamethoxazole; TMP/SMX) are all agents that are utilised for the treatment and/or prophylaxis of opportunistic infections in patients with AIDS. OBJECTIVE: To characterise the potential for an interaction when azithromycin is coadministered with cotrimoxazole or with fluconazole. DESIGN: Two separate nonblind randomised studies were conducted in healthy volunteers. During the fluconazole study the potential for fluconazole to adversely affect the pharmacokinetics of azithromycin was also studied. PARTICIPANTS: 24 (cotrimoxazole) and 18 (fluconazole) healthy male and female volunteers. RESULTS: The results of both studies indicated that neither the peak concentrations of nor the exposures (area under the concentration-time curve) to the test drugs were changed when azithromycin was coadministered. In addition, fluconazole did not significantly alter the pharmacokinetic parameters of azithromycin. CONCLUSIONS: Azithromycin does not alter the bioavailability of either cotrimoxazole or fluconazole.
BACKGROUND:Azithromycin, fluconazole and cotrimoxazole (trimethoprim-sulfamethoxazole; TMP/SMX) are all agents that are utilised for the treatment and/or prophylaxis of opportunistic infections in patients with AIDS. OBJECTIVE: To characterise the potential for an interaction when azithromycin is coadministered with cotrimoxazole or with fluconazole. DESIGN: Two separate nonblind randomised studies were conducted in healthy volunteers. During the fluconazole study the potential for fluconazole to adversely affect the pharmacokinetics of azithromycin was also studied. PARTICIPANTS: 24 (cotrimoxazole) and 18 (fluconazole) healthy male and female volunteers. RESULTS: The results of both studies indicated that neither the peak concentrations of nor the exposures (area under the concentration-time curve) to the test drugs were changed when azithromycin was coadministered. In addition, fluconazole did not significantly alter the pharmacokinetic parameters of azithromycin. CONCLUSIONS:Azithromycin does not alter the bioavailability of either cotrimoxazole or fluconazole.
Authors: D J Greenblatt; L L von Moltke; J S Harmatz; M Counihan; J A Graf; A L Durol; P Mertzanis; S X Duan; C E Wright; R I Shader Journal: Clin Pharmacol Ther Date: 1998-09 Impact factor: 6.875
Authors: S A Bozzette; R A Larsen; J Chiu; M A Leal; J Jacobsen; P Rothman; P Robinson; G Gilbert; J A McCutchan; J Tilles Journal: N Engl J Med Date: 1991-02-28 Impact factor: 91.245